Clinical Trial: Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional




Official Title: A Pilot Study of Dabrafenib for Patients With BRAF Mutated Ameloblastoma

Brief Summary: This pilot clinical trial studies dabrafenib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.